Shanghai Titan Scientific (688133)

Search documents
泰坦科技:泰坦科技关于完成工商变更登记并换发营业执照的公告
2023-08-10 07:41
证券代码:688133 证券简称:泰坦科技 公告编号:2023-048 上海泰坦科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司(以下简称"公司")于 2023 年 5 月 10 日召开第四届 董事会第四次会议、第四届监事会第四次会议,审议通过了《关于公司 2021 年限制性股 票激励计划第二个归属期符合归属条件的议案》等议案。公司于 2023 年 6 月 9 日收到中 国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》,2021 年限制性 股票激励计划第二个归属期归属登记完成,公司股本总数由 84,071,656 股增加至 84,263,856 股,公司注册资本由 8,407.1656 万元增加至 8,426.3856 万元。具体情况详 见公司于 2023 年 6 月 13 日披露在上海证券交易所网站(www.sse.com.cn)的《2021 年 限制性股票激励计划第二个归属期归属结果暨股份上市公告》(公告编号:2023-0 ...
泰坦科技:上海泰坦科技股份有限公司关于召开2022年度暨2023年第一季度业绩暨现金分红说明会的公告
2023-05-22 10:02
证券代码:688133 证券简称:泰坦科技 公告编号:2023-042 上海泰坦科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 会议召开时间:2023 年 05 月 30 日(星期二) 下午 14:00-15:00 会议召开地点:上海证券交易所上证路演中心 (网址:http://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 投资者可于 2023 年 05 月 23 日(星期二)至 05 月 29 日(星期一)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 contact@titansci.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海泰坦科技股份有限公司(以下简称"公司")已于 202 ...
泰坦科技(688133) - 2022 Q4 - 年度财报
2023-04-27 16:00
Financial Performance - In 2022, Titan Technology achieved a sales revenue of 2.608 billion yuan, representing a year-on-year growth of 20.50%[9]. - The net profit for 2022 was 124.81 million yuan, which reflects a decrease of 13.30% compared to the previous year[9]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year growth of 15%[32]. - The company achieved operating revenue of 2,607.89 million yuan in 2022, representing a year-on-year increase of 20.50%[53]. - The net profit attributable to shareholders decreased by 13.30% to CNY 124,808,388.08 in 2022 from CNY 143,954,310.29 in 2021[40]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% growth year-over-year[189]. - The company provided guidance for 2023, projecting revenue growth of 15% to 1.725 billion, driven by new product launches and market expansion strategies[190]. Dividend and Capital Plans - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 16.81 million yuan, which is 13.47% of the net profit[5]. - Titan Technology intends to increase its total share capital by 33.63 million shares through a capital reserve conversion, raising the total share capital to 117.70 million shares[5]. Research and Development - The company has achieved an average annual R&D investment growth of 61.10% over the past three years, with last year's R&D expenditure exceeding 126 million yuan[22]. - The company is investing RMB 100 million in R&D for new technologies aimed at enhancing product efficiency and reducing costs[32]. - The total R&D investment increased by 44.80% year-on-year, reaching approximately ¥126 million, with a significant rise in capitalized R&D investment by 108.85% to about ¥6.14 million[87]. - The company has filed 101 new invention patents and software copyrights, indicating a strong focus on innovation[22]. - The company is focused on technology innovation as a core competitive advantage, emphasizing self-innovation and increasing R&D investment[112]. Market Expansion and Strategy - Monthly sales revenue has shown a recovery since March 2023, with a year-on-year increase of over 45% and a growth of over 80% in the higher education market[9]. - The company plans to increase its market share in 66 small categories from 10% to over 50%, targeting sales revenue to exceed 10 billion yuan[24]. - Market expansion efforts are focused on Southeast Asia, with a target to increase market share by 20% in the region over the next two years[32]. - The company is expanding its international presence by establishing a wholly-owned subsidiary in Singapore and forming overseas marketing teams[24]. - The company is focused on expanding its product line by incorporating third-party products to meet diverse customer needs[76]. Operational Efficiency and Challenges - The company faces significant industry challenges, including increased competition and price wars, particularly in the chemical reagent sector, where gross margins have dropped to 25%[12]. - The company aims to optimize its operating cash flow, which has shown improvement compared to the previous year[41]. - The company is committed to enhancing inventory turnover and capital returns, recognizing significant gaps compared to international peers[21]. - The company has established a comprehensive quality management system to reduce quality complaint rates to the lowest level in the industry[22]. Acquisitions and Investments - The company has successfully completed 12 investment projects and acquired one foreign enterprise, resulting in a 55.19% increase in net profit for the acquired company in the second year[23]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of RMB 300 million allocated for this purpose[32]. - The company completed the acquisition and integration of Anhui Tiandi, achieving self-production capabilities in high-purity solvent product lines[67]. Governance and Management - The board of directors convened 11 meetings in 2022, consisting of 9 members, including 3 independent directors, to ensure effective governance and decision-making[178]. - The company held a total of 5 shareholder meetings during the reporting period, ensuring compliance with legal procedures and allowing all shareholders to exercise their voting rights[178]. - The internal control system was improved, enhancing the company's risk prevention capabilities and operational standards[180]. Customer Engagement and Satisfaction - User data indicated an increase in active users by 25% compared to the previous year, reaching a total of 500,000 active users[32]. - Customer satisfaction ratings improved to 90%, reflecting a 5% increase from the previous year[189]. - The company plans to implement new marketing strategies, expecting a 12% increase in customer engagement[189]. Financial Health and Risks - The total assets of the company increased by 12% year-over-year, reaching RMB 3 billion as of the end of 2022[32]. - The company's inventory value was 850 million yuan, making up 21.41% of total assets, which poses a risk of overstock and management challenges[120]. - The company faces risks related to core technology leakage due to its reliance on OEM manufacturers for production, which could impact its competitive advantage[116].
泰坦科技(688133) - 2023 Q1 - 季度财报
2023-04-27 16:00
[Major Financial Data](index=1&type=section&id=Item%201.%20Major%20Financial%20Data) [Major Accounting Data and Financial Metrics](index=1&type=section&id=Item%201.%281%29Major%20Accounting%20Data%20and%20Financial%20Metrics) The company achieved **655 million CNY** in Q1 2023 operating revenue, growing **12.68%**, with net profit increasing **29.17%** to **25.10 million CNY** and R&D investment reaching **5.68%** of revenue Key Financial Metrics for Q1 2023 | Metric | Current Period | Year-over-Year Change (%) | | :--- | :--- | :--- | | Operating Revenue | 655 million CNY | 12.68% | | Net Profit Attributable to Shareholders | 25.10 million CNY | 29.17% | | Net Profit Attributable to Shareholders (Excl. Non-Recurring) | 22.52 million CNY | 39.49% | | Net Cash Flow from Operating Activities | -158 million CNY | N/A | | Basic EPS (CNY/share) | 0.30 CNY | 20.00% | | Total R&D Investment | 37.23 million CNY | 16.25% | | R&D Investment as % of Operating Revenue | 5.68% | +0.17 percentage points | Key Balance Sheet Metrics at Period End | Metric | End of Current Period | Change from End of Previous Year (%) | | :--- | :--- | :--- | | Total Assets | 3.997 billion CNY | 0.63% | | Total Equity Attributable to Shareholders | 2.751 billion CNY | 1.15% | [Non-Recurring Gains/Losses Items and Amounts](index=2&type=section&id=Item%201.%282%29Non-Recurring%20Gains%2FLosses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains/losses amounted to **2.58 million CNY**, primarily from government grants recognized in current period profit and loss Q1 2023 Non-Recurring Gains/Losses Details | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | -12,521.64 | | Government Grants Recognized in Current Period P&L | 3,486,752.05 | | Fair Value Changes from Trading Financial Assets, etc. | 41,133.46 | | Other Non-Operating Income and Expenses | -31,726.87 | | Less: Income Tax Impact | 535,080.26 | | Less: Impact of Minority Interests (After Tax) | 372,347.07 | | **Total** | **2,576,209.67** | [Analysis of Major Financial Metric Changes](index=3&type=section&id=Item%201.%283%29Analysis%20of%20Major%20Accounting%20Data%2C%20Financial%20Metric%20Changes%20and%20Reasons) The company's net profit excluding non-recurring items grew **39.49%**, significantly outpacing revenue growth due to stable expenses and improved marginal benefits - The **39.49%** growth in net profit excluding non-recurring items was primarily driven by sustained revenue growth in Q1 coupled with relatively stable expenses, leading to improved marginal benefits and a higher profit growth rate than revenue growth[8](index=8&type=chunk)[9](index=9&type=chunk) [Shareholder Information](index=4&type=section&id=Item%202.%20Shareholder%20Information) [Shareholding Status of Shareholders](index=4&type=section&id=Item%202.%281%29Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the reporting period end, the company had **5,374** common shareholders, with the top five being concerted parties, indicating a relatively concentrated ownership structure that includes various institutional investors - At the end of the reporting period, the company had **5,374** common shareholders[11](index=11&type=chunk) - The company's top five shareholders, Xie Yingbo, Zhang Qing, Zhang Mo, Xu Fengyuan, and Wang Jingyu, are concerted parties[12](index=12&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholding Percentage (%) | Shareholder Type | | :--- | :--- | :--- | | Xie Yingbo | 9.85 | Domestic Individual | | Zhang Qing | 4.57 | Domestic Individual | | Zhang Mo | 4.57 | Domestic Individual | | Wang Jingyu | 4.57 | Domestic Individual | | Xu Fengyuan | 4.57 | Domestic Individual | | Suzhou Zhongding No. 5 Equity Investment Partnership (LP) | 3.72 | Domestic Non-State-Owned Legal Person | | Tianjin Chuangfeng Xinhu Venture Capital Partnership (LP) | 2.75 | Domestic Non-State-Owned Legal Person | | GF Securities Co., Ltd. | 1.81 | State-Owned Legal Person | | National Council for Social Security Fund 418 Portfolio | 1.71 | State-Owned Legal Person | | Shanghai Science and Technology Venture Capital Co., Ltd. | 1.45 | State-Owned Legal Person | [Other Reminders](index=5&type=section&id=Item%203.%20Other%20Reminders) [Other Important Information](index=5&type=section&id=Item%203.%20Other%20Reminders) The company has no other significant operational information requiring special investor attention during this reporting period - There is no other significant operational information regarding the company's business that requires investor attention during the reporting period[13](index=13&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=Item%204.%20Quarterly%20Financial%20Statements) [Type of Audit Opinion](index=5&type=section&id=Item%204.%281%29Type%20of%20Audit%20Opinion) The financial statements for this quarter are unaudited - The company's Q1 2023 financial statements are unaudited[4](index=4&type=chunk)[13](index=13&type=chunk) [Financial Statements](index=6&type=section&id=Item%204.%282%29Financial%20Statements) This section presents the company's unaudited consolidated balance sheet, income statement, and cash flow statement for Q1 2023 [Consolidated Balance Sheet](index=6&type=section&id=Consolidated%20Balance%20Sheet) As of March 31, 2023, total assets were **3.997 billion CNY**, a **0.63%** increase from year-end, with current assets comprising approximately **78%**, while total liabilities decreased slightly to **1.198 billion CNY**, and equity attributable to parent company shareholders grew **1.15%** to **2.751 billion CNY** Key Balance Sheet Items (Unit: Billion CNY) | Item | March 31, 2023 | December 31, 2022 | Change | | :--- | :--- | :--- | :--- | | **Total Assets** | **3.997** | **3.972** | **+0.63%** | | Cash and Cash Equivalents | 1.161 | 1.390 | -16.47% | | Accounts Receivable | 0.736 | 0.610 | +20.66% | | Inventories | 0.910 | 0.850 | +7.06% | | **Total Liabilities** | **1.198** | **1.205** | **-0.60%** | | Short-term Borrowings | 0.485 | 0.509 | -4.71% | | **Equity Attributable to Parent Company Shareholders** | **2.751** | **2.720** | **+1.15%** | [Consolidated Income Statement](index=8&type=section&id=Consolidated%20Income%20Statement) In Q1 2023, the company achieved **655 million CNY** in total operating revenue, a **12.68%** year-over-year increase, with improved gross margin due to controlled operating costs, and net profit attributable to parent company shareholders reaching **25.10 million CNY**, up **29.17%** Key Income Statement Items (Unit: Billion CNY) | Item | Q1 2023 | Q1 2022 | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 0.655 | 0.582 | +12.68% | | Total Operating Costs | 0.623 | 0.560 | +11.17% | | Including: Operating Costs | 0.507 | 0.464 | +9.29% | | Selling Expenses | 0.045 | 0.039 | +17.19% | | Administrative Expenses | 0.028 | 0.021 | +32.77% | | R&D Expenses | 0.036 | 0.030 | +21.30% | | Operating Profit | 0.028 | 0.021 | +32.42% | | **Net Profit Attributable to Parent Company Shareholders** | **0.025** | **0.019** | **+29.17%** | | **Basic EPS (CNY/share)** | **0.30** | **0.25** | **+20.00%** | [Consolidated Cash Flow Statement](index=11&type=section&id=Consolidated%20Cash%20Flow%20Statement) In Q1 2023, net cash flow from operating activities was **-158 million CNY**, a significant improvement from **-226 million CNY** in the prior year, with net cash outflows from investing and financing activities of **55 million CNY** and **11 million CNY**, respectively, and cash and cash equivalents at period end totaling **1.156 billion CNY** Key Cash Flow Statement Items (Unit: Billion CNY) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -0.158 | -0.226 | | Net Cash Flow from Investing Activities | -0.055 | -0.226 | | Net Cash Flow from Financing Activities | -0.011 | 0.333 | | Net Increase in Cash and Cash Equivalents | -0.225 | -0.119 | | Cash and Cash Equivalents at Period End | 1.156 | 0.542 |